Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02472184 · ClinicalTrials.gov registry record · NA

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

A NA study of Uterine Fibroids and Vaginal Bleeding, sponsored by University of South Florida.

Completed
Registry status
NA
Development phase
78
Enrollment target
1
Study location

NCT02472184 is a NA study of Uterine Fibroids and Vaginal Bleeding that has completed, run by University of South Florida. The registered enrollment target is 78 participants, below the 236-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02472184, a NA study of Uterine Fibroids and Vaginal Bleeding, has completed, sponsored by University of South Florida.

COMPLETED
Registry status
NA
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

This study will look at the optimal order in which to perform concurrent office hysteroscopy and endometrial biopsy in female patients who present for evaluation of abnormal uterine bleeding at a fibroid and endometriosis treatment center.

Interventions

  • PROCEDURE Endometrial biopsy
  • PROCEDURE Office hysteroscopy

Study Locations (1)

Florida

  • University of South Florida College of Medicien Department of Obstetrics and Gynecology - Tampa

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2015-10
Est. Completion 2017-03
Phase NA

Sponsor

University of South Florida

252 total trials

What the Registry Record Tells You About NCT02472184

The ClinicalTrials.gov registry entry for NCT02472184 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 236-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (67% lower). The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Uterine Fibroids appearing as the primary indexed condition, and to 2 interventions - of which Endometrial biopsy is the first listed.

NCT02472184 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT02472184 about?

NCT02472184 is a clinical study titled "Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy". This study will look at the optimal order in which to perform concurrent office hysteroscopy and endometrial biopsy in female patients who present for evaluation of abnormal uterine bleeding at a fibroid and endometriosis treatment center.

What is the current status of trial NCT02472184?

This trial is currently completed. It is a NA study. The enrollment target is 78 participants. The study started on 2015-10. Estimated completion is 2017-03.

What conditions does trial NCT02472184 study?

This clinical trial studies the following conditions: Uterine Fibroids, Vaginal Bleeding.

What interventions are being tested in trial NCT02472184?

The interventions under investigation include: Endometrial biopsy (PROCEDURE), Office hysteroscopy (PROCEDURE).

Who is sponsoring clinical trial NCT02472184?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02472184 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uterine Fibroids

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.